HighTower Advisors LLC Sells 1,657 Shares of Progyny, Inc. (NASDAQ:PGNY)

HighTower Advisors LLC lessened its position in Progyny, Inc. (NASDAQ:PGNY) by 12.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,145 shares of the company’s stock after selling 1,657 shares during the quarter. HighTower Advisors LLC’s holdings in Progyny were worth $181,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC lifted its position in shares of Progyny by 1,576.0% during the 3rd quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock worth $42,991,000 after purchasing an additional 2,412,068 shares during the last quarter. Pacer Advisors Inc. increased its position in Progyny by 12,579.4% during the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company’s stock worth $41,777,000 after acquiring an additional 2,472,983 shares during the period. Farallon Capital Management LLC raised its stake in Progyny by 120.8% during the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after purchasing an additional 715,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Progyny by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company’s stock valued at $36,676,000 after purchasing an additional 254,725 shares during the period. Finally, Kornitzer Capital Management Inc. KS increased its holdings in shares of Progyny by 15.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 976,501 shares of the company’s stock worth $16,366,000 after purchasing an additional 132,672 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Price Performance

NASDAQ:PGNY opened at $14.53 on Thursday. The firm’s fifty day moving average price is $15.27 and its two-hundred day moving average price is $20.63. The company has a market cap of $1.24 billion, a P/E ratio of 25.05, a P/E/G ratio of 1.64 and a beta of 1.35. Progyny, Inc. has a one year low of $13.39 and a one year high of $42.08.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million during the quarter, compared to the consensus estimate of $296.85 million. During the same period in the previous year, the firm posted $0.16 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. As a group, equities research analysts expect that Progyny, Inc. will post 0.59 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on PGNY shares. JPMorgan Chase & Co. restated a “neutral” rating and set a $17.00 price objective (down from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of Progyny in a research note on Tuesday, October 1st. Jefferies Financial Group decreased their target price on shares of Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Canaccord Genuity Group cut their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Finally, Barclays lowered their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Progyny presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.